BOSTON--(BUSINESS WIRE)--Tomorrow, Dr. Bill Hearl, Ph.D., Chief Executive Officer (CEO) of Immunomic Therapeutics, Inc. will present at the Immuno-Oncology Summit in Boston, Massachusetts. The presentation, “Addressing the Challenges of Viral Targets in Cancer," will discuss the study of Immunomic’s Investigational UNITE, or UNiversal Intracellular Targeted Expression, technology platform as applied to oncology research. Immunomic Therapeutics’ nucleic acid vaccines have the potential to utilize the body’s natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. This approach could put UNITE at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. Immunomic’s lysosomal targeting technology is currently being employed in a Phase II clinical trial as a cancer immunotherapy.
|
Who: |
Dr. Bill Hearl, Ph.D., CEO at Immunomic Therapeutics, Inc. | |
|
What: |
Presentation at Immuno-Oncology Summit: Addressing the Challenges of Viral Targets in Cancer | |
|
When: |
Tomorrow, Thursday, August 30, 3 p.m. EDT | |
|
Where: |
Seaport World Trade Center, 200 Seaport Boulevard, Boston, MA 02210 | |
| Personalized Cancer Vaccine Track, The Skyline Room | ||
About UNITE
ITI’s investigational UNITE platform, or UNiversal Intracellular Targeted Expression, is thought to work by encoding the Lysosomal Associated Membrane Protein, an endogenous protein in humans. In this way, ITI’s vaccines (DNA or RNA) have the potential to utilize the body’s natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. This approach could put UNITE technology at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. UNITE is currently being employed in Phase II clinical trials as a cancer immunotherapy. ITI is also collaborating with academic centers and biotechnology companies to study the use of UNITE in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma and acute myeloid leukemia. ITI believes that these early clinical studies may provide a proof of concept for UNITE therapy in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. Preclinical data is currently being developed to explore whether LAMP nucleic acid constructs may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response.
About Immunomic Therapeutics, Inc.
Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the LAMP-based nucleic acid immunotherapy platforms. These investigational technologies have the potential to alter how we use immunotherapy for cancer, allergies and animal health. ITI has entered into a significant licensing agreement with Astellas Pharma Inc. to explore the use of LAMP-Vax, the precursor to UNITE, an immunotherapy platform, for use in the prevention and treatment of allergic diseases. For information about ITI and UNITE technology, visit www.immunomix.com.
